이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Hofseth BioCare 미래 성장

Future 기준 확인 0/6

현재 Hofseth BioCare 의 성장과 수익을 예측할 만큼 분석가의 범위가 충분하지 않습니다.

주요 정보

n/a

수익 성장률

n/a

EPS 성장률

Biotechs 수익 성장	-8.5%
매출 성장률	n/a
향후 자기자본 수익률	n/a
애널리스트 커버리지	None
마지막 업데이트	n/a

최근 미래 성장 업데이트

Recent updates

Hofseth BioCare (OB:HBC) Shareholders Have Enjoyed A Whopping 339% Share Price Gain

Nov 20

이 섹션에서는 일반적으로 투자자가 회사의 수익 창출 능력을 이해하는 데 도움이 되도록 전문 애널리스트의 컨센서스 추정치를 기반으로 수익 및 수익 성장 전망치를 제시합니다. 하지만 Hofseth BioCare 은 충분한 과거 데이터를 제공하지 않았고 애널리스트 예측도 없기 때문에 과거 데이터를 추정하거나 애널리스트 예측을 사용하여 미래 수익을 안정적으로 계산할 수 없습니다.

SimplyWall St에서 다루는 기업의 97%가 과거 재무 데이터를 가지고 있기 때문에 이는 매우 드문 상황입니다.

수익 및 매출 성장 예측

OB:HBC - 애널리스트의 미래 추정치 및 과거 재무 데이터 (NOK Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
3/31/2024	226	-98	-28	-17	N/A
12/31/2023	219	-107	-11	3	N/A
9/30/2023	205	-93	43	61	N/A
6/30/2023	185	-105	-6	11	N/A
3/31/2023	134	-140	-54	-36	N/A
12/31/2022	120	-137	-63	-45	N/A
9/30/2022	113	-136	-133	-114	N/A
6/30/2022	96	-139	-110	-90	N/A
3/31/2022	102	-135	-84	-53	N/A
12/31/2021	88	-126	-100	-62	N/A
9/30/2021	85	-120	-103	-59	N/A
6/30/2021	79	-115	-100	-43	N/A
3/31/2021	68	-111	-114	-56	N/A
12/31/2020	69	-102	-116	-62	N/A
9/30/2020	57	-104	-103	-54	N/A
6/30/2020	79	-90	-99	-63	N/A
3/31/2020	72	-86	-73	-49	N/A
12/31/2019	68	-89	-51	-31	N/A
9/30/2019	71	-79	19	25	N/A
6/30/2019	59	-81	-36	-36	N/A
3/31/2019	61	-83	-31	-23	N/A
12/31/2018	61	-85	-38	-29	N/A
9/30/2018	73	-74	-104	-81	N/A
6/30/2018	84	-66	-28	-3	N/A
3/31/2018	75	-66	-36	-20	N/A
12/31/2017	66	-16	N/A	-25	N/A
9/30/2017	43	-28	N/A	-18	N/A
6/30/2017	19	-60	N/A	-43	N/A
3/31/2017	21	-92	N/A	-70	N/A
12/31/2016	20	-147	N/A	-67	N/A
9/30/2016	21	-165	N/A	-8	N/A
6/30/2016	34	-137	N/A	-2	N/A
3/31/2016	32	-109	N/A	1	N/A
12/31/2015	32	-100	N/A	8	N/A
9/30/2015	38	-84	N/A	-54	N/A
6/30/2015	23	-82	N/A	-47	N/A
3/31/2015	24	-72	N/A	-72	N/A
12/31/2014	20	-67	N/A	-61	N/A
9/30/2014	39	-40	N/A	-70	N/A
6/30/2014	62	-35	N/A	-103	N/A
3/31/2014	63	-39	N/A	-58	N/A
12/31/2013	63	-52	N/A	-77	N/A
9/30/2013	41	-98	N/A	-81	N/A

애널리스트 미래 성장 예측

수입 대 저축률: HBC 의 예상 수익 증가율이 절약률( 2.1% )보다 높은지 판단하기에는 데이터가 부족합니다.

수익 vs 시장: HBC 의 수익이 Norwegian 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

고성장 수익: HBC 의 수익이 향후 3년 동안 상당히 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

수익 대 시장: HBC 의 수익이 Norwegian 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

고성장 수익: HBC 의 수익이 연간 20% 보다 빠르게 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: HBC 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

Hofseth BioCare 미래 성장

Future 기준 확인 0/6

주요 정보

최근 미래 성장 업데이트

Hofseth BioCare ASA Provides Earnings Guidance for the Second Half of 2021 and Next Year 2022

Recent updates

Less than half of directors are independent

First quarter 2024 earnings released: kr0.07 loss per share (vs kr0.096 loss in 1Q 2023)

Full year 2023 earnings released: kr0.27 loss per share (vs kr0.37 loss in FY 2022)

New minor risk - Share price stability

Hofseth BioCare ASA Announces Board Changes

New major risk - Financial position

Full year 2023 earnings released: kr0.27 loss per share (vs kr0.37 loss in FY 2022)

Hofseth BioCare ASA to Report Q4, 2024 Results on Feb 14, 2025

Third quarter 2023 earnings released: kr0.06 loss per share (vs kr0.09 loss in 3Q 2022)

New minor risk - Market cap size

Second quarter 2023 earnings released: EPS: kr0.015 (vs kr0.079 loss in 2Q 2022)

CFO & COO recently bought kr200k worth of stock

New minor risk - Market cap size

Hofseth Biocare ASA Announces the Online Publication of Its Abstract

First quarter 2023 earnings released: kr0.10 loss per share (vs kr0.10 loss in 1Q 2022)

Here's Why Hofseth BioCare (OB:HBC) Can Afford Some Debt

Chief Scientific Officer recently bought kr538k worth of stock

Independent Director recently bought kr272k worth of stock

Full year 2022 earnings released: kr0.37 loss per share (vs kr0.35 loss in FY 2021)

We Think Hofseth BioCare (OB:HBC) Has A Fair Chunk Of Debt

Hofseth BioCare ASA to Report Fiscal Year 2022 Results on Mar 31, 2023

Third quarter 2022 earnings released: kr0.09 loss per share (vs kr0.11 loss in 3Q 2021)

Third quarter 2022 earnings released: kr0.09 loss per share (vs kr0.11 loss in 3Q 2021)

Hofseth BioCare ASA's Progo Bioactive Peptides Now Is A "New Dietary Ingredient" for the US FDA

Second quarter 2022 earnings released: kr0.08 loss per share (vs kr0.069 loss in 2Q 2021)

Hofseth BioCare ASA Announces Executive Changes

Chief Executive Officer recently bought kr170k worth of stock

First quarter 2022 earnings released: kr0.10 loss per share (vs kr0.075 loss in 1Q 2021)

Health Check: How Prudently Does Hofseth BioCare (OB:HBC) Use Debt?

Full year 2021 earnings released: kr0.35 loss per share (vs kr0.31 loss in FY 2020)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Chief Executive Officer recently bought kr367k worth of stock

Hofseth Biocare ASA Successfully Receive New Dietary Ingredient (NDI) Status from the US FDA

Third quarter 2021 earnings released: kr0.11 loss per share (vs kr0.10 loss in 3Q 2020)

Hofseth BioCare (OB:HBC) Is Carrying A Fair Bit Of Debt

Chief Commercial Officer recently bought kr200k worth of stock

Chief Executive Officer recently bought kr361k worth of stock

Second quarter 2021 earnings released: kr0.07 loss per share (vs kr0.062 loss in 2Q 2020)

Hofseth BioCare ASA Provides Earnings Guidance for the Second Half of 2021 and Next Year 2022

Independent Director recently bought kr385k worth of stock

First quarter 2021 earnings released: kr0.08 loss per share (vs kr0.055 loss in 1Q 2020)

Full year 2020 earnings released: kr0.31 loss per share (vs kr0.29 loss in FY 2019)

Is Hofseth BioCare (OB:HBC) Using Debt Sensibly?

Full year 2020 earnings released: kr0.31 loss per share (vs kr0.29 loss in FY 2019)

How Much Of Hofseth BioCare ASA (OB:HBC) Do Insiders Own?

Chief Executive Officer recently bought kr505k worth of stock

Chief Executive Officer recently bought kr505k worth of stock

Chief Executive Officer recently bought kr505k worth of stock

New 90-day high: kr9.80

Are Insiders Buying Hofseth BioCare ASA (OB:HBC) Stock?

Hofseth BioCare ASA has completed a Follow-on Equity Offering in the amount of NOK 39.999995 million.

Hofseth Biocare ASA and Tenet Partners Initiate A Long-Term Collaboration to Build A Global Brand and Launch HBC Own Branded Consumer Health Products

Hofseth BioCare ASA and DKSH Announces A Pan-Asian Exclusive Collaboration for Distribution of HBC Branded Products Including Across China, India, Japan & Korea

Hofseth Biocare Asa Signs Exclusive Distribution Agreement with Leading Speciality Chemicals and Ingredients Distributor IMCD

Hofseth Biocare ASA Hires Andy Gill as VP from January 2021

Hofseth BioCare ASA, Annual General Meeting, Apr 23, 2021

Hofseth BioCare (OB:HBC) Shareholders Have Enjoyed A Whopping 339% Share Price Gain

Hofseth Biocare ASA Approves Appointment of Christoph Baldegger as New Member of the Audit Committee

Third quarter earnings released

New 90-day low: kr7.98

HBC Receives Approval from Health Canada for Qualified Health Claims Focused on Maintaining Healthy Levels of Ferritin and Hemoglobin and the Blood Components Required for Oxygen Transport

Hofseth BioCare ASA has completed a Follow-on Equity Offering in the amount of NOK 200 million.

Hofseth Biocare ASA's Progo’s Bioactive Peptides to Support Healthy Iron Levels to Be Launched in the US

Hofseth BioCare ASA Announces the First Part of its Accelerated Phase 2 Trial of Cardio™ Soft Gels for the Treatment of Patients with COVID-19

New 90-day low - kr8.16

First half earnings released

Hofseth BioCare ASA (OB:HBC) acquired a 34% stake in Atlantic Delights Ltd. for $0.7 million.

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견